9989 — Shenzhen Hepalink Pharmaceutical Co Balance Sheet
0.000.00%
Last trade - 00:00HealthcareAdventurousMid CapValue Trap
- HK$6.43bn
- HK$10.14bn
- CNY7.16bn
- 32
- 72
- 37
- 43
Annual balance sheet for Shenzhen Hepalink Pharmaceutical Co, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
R2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | CAS | CAS | CAS | CAS | CAS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 1,940 | 1,329 | 3,541 | 3,873 | 3,334 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 1,377 | 1,752 | 2,026 | 1,938 | 1,927 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 5,599 | 5,996 | 9,129 | 10,770 | 12,390 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 2,439 | 2,576 | 2,571 | 2,537 | 2,477 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 13,602 | 15,242 | 19,026 | 19,108 | 20,814 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 4,663 | 4,967 | 3,613 | 4,791 | 5,576 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 7,612 | 7,895 | 7,457 | 7,697 | 8,503 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Unrealized Gain / Loss | |||||
| Other Equity | |||||
| Total Equity | 5,990 | 7,347 | 11,569 | 11,411 | 12,311 |
| Total Liabilities & Shareholders' Equity | 13,602 | 15,242 | 19,026 | 19,108 | 20,814 |
| Total Common Shares Outstanding |